Innorna
@innorna.com
Innorna is a clinical-stage biotechnology company engineering mRNA-based medicines to treat chronic diseases, power in vivo immunotherapies, and prevent infectious diseases ā improving lives worldwide.
Innorna's Company Logos
Innorna's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#787D85
Rolling Stone
120, 125, 133
217, 5, 50
10, 6, 0, 48
#F0AE58
Sandy brown
240, 174, 88
34, 84, 64
0, 27, 63, 6
#35175A
Scarlet Gum
53, 23, 90
267, 59, 22
41, 74, 0, 65
About Innorna
Innorna is a pioneering platform-based company established in 2019 that specializes in the research and development of nucleic acid therapeutics delivery platforms. With expertise in mRNA delivery and proprietary LNP and mRNA technologies, Innorna has filed 34 invention patents globally. Collaborating with international and domestic pharmaceutical companies, we aim to co-develop nucleic acid drugs or license-out LNPs for nucleic acid therapeutics.
Our pipeline focuses on a wide range of therapeutic areas, including infectious diseases, oncology, rare diseases, and autoimmune diseases, with some products already in the clinical phase. With a strong financial backing of over $140 million from reputable venture capital firms, we have assembled an exceptionally talented team comprising almost 200 employees, including a dedicated R&D workforce.
Headquartered in China, Innorna is committed to pushing the boundaries of mRNA application and leading the charge in expanding its clinical usage globally. We emphasize the values of INNOVATION, INTEGRITY, EFFICIENCY, and OPENNESS.
With a comprehensive infrastructure that includes a 5,000+ LNP library, a 150+ R&D and CMC team, a 2,500ć” GMP facility, and a 4,500ć” research laboratory, we have the resources necessary to drive groundbreaking advancements in the field of nucleic acid therapeutics.
Innorna was founded by Dr. Li Linxian, an assistant professor at Karolinska Institute and one of "35 Innovators Under 35 in China" according to MIT Technology Review. With a passion for utilizing innovative technologies to address unmet medical needs, Dr. Li and his team have developed a next-generation LNP platform for mRNA delivery. His contributions have earned him recognition as one of the "40 Under 40 Business Elites in China" by Fortune in 2023.
To learn more about Innorna, please visit our website or get in touch with our offices in Shenzhen, Hong Kong, or Nanjing. We are dedicated to fulfilling the unmet medical needs of patients worldwide through our tireless pursuit of technological advancements in mRNA therapeutics.
Ā© 2023 Innorna Co. Ltd. ALL RIGHTS REVERSED. Design by sumaart.
Company type
Privately Held
Year founded
2019
Company size
51-200 employees
